Q-omics provides the consensus-scored SLMAP profile across patient tissues and cancer cell-line models. SLMAP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SLMAP is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SLMAP RNA expression shows 21,048 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, BLCA, and THYM as cancer lineages where SLMAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLMAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLMAP survival associations across molecular data types. SLMAP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLMAP RNA expression–survival associations across cancer types. High SLMAP expression shows unfavorable associations in LUAD, ACC and PAAD, but favorable associations in KIRC, SKCM and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SLMAP RNA expression.
This table summarizes SLMAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLMAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLMAP shows lower tumor expression in BLCA, THCA, KIRC, COAD and UCEC and higher tumor expression in LIHC. The BLCA box plot shows higher SLMAP RNA expression in normal versus tumor tissue (log2 FC = −1.899, t-test p < 0.001).
This table shows molecular features associated with SLMAP in patient tissues and cancer cell lines. In patient samples, SLMAP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLMAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
